# Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

> **NCT03808558** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **David E Gerber** · enrollment: 18 (actual)

## Conditions studied

- KRAS Gene Mutation

## Interventions

- **DRUG:** TVB-2640

## Key facts

- **NCT ID:** NCT03808558
- **Lead sponsor:** David E Gerber
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-11
- **Primary completion:** 2025-04-03
- **Final completion:** 2026-12-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03808558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03808558, "Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03808558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*